Company Name: Avita Medical
Announcement Date: 11/07/2016
Announcement Category: Contract/Partnership, Product launch/update
Announcement Content:
Avita Medical Limited (ASX:AVH; OTCQX:AVMXY) has engaged a leading Health Economics Group to evaluate how its novel regenerative medical device, ReCell®, can save money at US burns centres, the Company said today.
The regenerative medicine company, which specializes in new treatments for wounds and skin defects, said the commissioned study would be funded by BARDA, the US federal authority which prepares the US for possible mass casualty events, and with which Avita has a US$61.9m (A$84.2m) development and procurement contract. IMS Health, one of the world’s leading health economic groups, had been selected for the project, which should take six to eight months, and has a broad remit to explore the potential cost savings from all major interventions for burns treatment, including wound bed preparation, grafting and scar management. Read more here: http://bit.ly/29x3UiE
Announcement URL: http://3af4pk1d7ktnf8ieb2pl91t1.wpengine.netdna-cdn.com/wp-content/uploads/2016/07/AVH-ASX-Release-IMS-Health-Economics-28June2016-FINAL.pdf
About Avita Medical:
Avita Medical is a medical device company that transforms lives through its unique and innovative skin regeneration solutions. We are a publicly listed, global medical technology company trading on the Australian Stock Exchange (ASX:AVH) and OTC Markets (OTCQX:AVMXY). We develop and distribute highly innovative regenerative products including ReCell, the revolutionary 'spray-on skin' invented by West Australian Professor Fiona Wood.
Go to Company Profile for: Avita Medical
Announcement Contact: [email protected]
